Interestingly, in silico modeling and in vitro testing of two selective estrogen receptor modulators (SERMs), raloxifene and bazedoxifene, revealed that they are able to bind to gp130, selectively downregulate IL-6-mediated STAT3 phosphorylation, and significantly inhibit STAT3 activity in ER- SUM159 breast cancer cells [81]. The gene discussed is STAT3; the disease is breast carcinoma.